Laureen Majed1, Xavier Bresse2, Nadia El Mouaddin3, Aurélie Schmidt4, Vincent J Daniels5, Andrew Pavelyev6, Laurie Levy-Bachelot7, Elamin Elbasha5. 1. Market Access, MSD France, Puteaux, France. Electronic address: laureenmajed@free.fr. 2. Market Access, MSD Vaccins, Lyon, France. 3. ICON plc, Nanterre, France. 4. ICON plc, Lyon, France. 5. EDS Center for Observational and Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA. 6. HCL America, Inc., Sunnyvale, CA, USA. 7. Market Access, MSD France, Puteaux, France.
Abstract
OBJECTIVES: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of the study were to assess the public health impact and cost-effectiveness of a 9-valent GNV compared with girls-only vaccination program (GOV). METHODS: A published HPV disease transmission dynamic model accounting for herd protection effects with a 100-year time horizon was adapted and calibrated to French data. Epidemiological and economic outcomes included disease cases averted and quality-adjusted life years (QALY). Costs and incremental cost-effectiveness ratio (ICER) were measured in 2018 Euros (€). A coverage rate of 26.2% among girls and boys was assumed for the GNV program based on the current female coverage rate in France. The base case included genital warts, cervical, vulvar, vaginal, and anal cancers. Scenario analyses included all HPV-related diseases and considered higher vaccination coverage rate (60%). Deterministic sensitivity analyses on key inputs were performed. RESULTS: Over 100 years, GNV resulted in an additional reduction of 9,519 and 3,037 cervical cancer cases and deaths; 6,901 and 1,166 additional anal cancer cases and deaths; and a reduction of additional 1,284,077 genital warts compared with current GOV and an ICER of 24,763€/QALY. When including all HPV-related diseases, the ICER was 15,184€/QALY. At a higher coverage rate (60%), GNV would prevent 17,430 and 4,334 additional anogenital cancer cases and deaths and over two million genital warts compared with GOV with an ICER of 40,401€/QALY. Results were sensitive to a higher discount rate (6% versus 4%) and a shorter duration of protection (20 years versus lifetime). CONCLUSIONS: In France, GNV has a significant impact in terms of public health benefits and may be considered cost-effective compared with GOV at low and high coverage rates.
OBJECTIVES: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of the study were to assess the public health impact and cost-effectiveness of a 9-valent GNV compared with girls-only vaccination program (GOV). METHODS: A published HPV disease transmission dynamic model accounting for herd protection effects with a 100-year time horizon was adapted and calibrated to French data. Epidemiological and economic outcomes included disease cases averted and quality-adjusted life years (QALY). Costs and incremental cost-effectiveness ratio (ICER) were measured in 2018 Euros (€). A coverage rate of 26.2% among girls and boys was assumed for the GNV program based on the current female coverage rate in France. The base case included genital warts, cervical, vulvar, vaginal, and anal cancers. Scenario analyses included all HPV-related diseases and considered higher vaccination coverage rate (60%). Deterministic sensitivity analyses on key inputs were performed. RESULTS: Over 100 years, GNV resulted in an additional reduction of 9,519 and 3,037 cervical cancer cases and deaths; 6,901 and 1,166 additional anal cancer cases and deaths; and a reduction of additional 1,284,077 genital warts compared with current GOV and an ICER of 24,763€/QALY. When including all HPV-related diseases, the ICER was 15,184€/QALY. At a higher coverage rate (60%), GNV would prevent 17,430 and 4,334 additional anogenital cancer cases and deaths and over two million genital warts compared with GOV with an ICER of 40,401€/QALY. Results were sensitive to a higher discount rate (6% versus 4%) and a shorter duration of protection (20 years versus lifetime). CONCLUSIONS: In France, GNV has a significant impact in terms of public health benefits and may be considered cost-effective compared with GOV at low and high coverage rates.
Authors: Steven Simoens; Andre Bento-Abreu; Barbara Merckx; Sophie Joubert; Steve Vermeersch; Andrew Pavelyev; Stefan Varga; Edith Morais Journal: Front Pharmacol Date: 2021-04-12 Impact factor: 5.810
Authors: Marco Bandini; Mohamed Ahmed; Giuseppe Basile; Nicholas Watkin; Viraj Master; Yao Zhu; Gagan Prakash; Alejandro Rodriguez; Mbaaga K Ssebakumba; Riccardo Leni; Giuseppe Ottone Cirulli; Ben Ayres; Rachel Compitello; Filippo Pederzoli; Pankaj M Joshi; Sanjay B Kulkarni; Francesco Montorsi; Guru Sonpavde; Andrea Necchi; Philippe E Spiess Journal: Nat Rev Urol Date: 2021-12-22 Impact factor: 16.430
Authors: Cintia Muñoz-Quiles; Javier Díez-Domingo; Luis Acedo; Víctor Sánchez-Alonso; Rafael J Villanueva Journal: Viruses Date: 2021-05-13 Impact factor: 5.048